Eon Labs ELAB
-
New Morningstar Analyst Report - Novartis AG ADR
… Further, the company bolstered its presence in the generics, vaccine and eye-care businesses through acquiring Hexal, Eon Labs , and Chiron, as well as an expected majority stake in Alcon. In an industry plagued by stagnant growth, Novartis emerges …
-
New Morningstar Analyst Report - Novartis AG ADR
… Further, the company bolstered its presence in the generics, vaccine and eye-care businesses through acquiring Hexal, Eon Labs , and Chiron, as well as an expected majority stake in Alcon. In an industry plagued by stagnant growth, Novartis emerges …
-
Innovation Booming in Emerging Markets Despite Obstacles
… conducted by the Fundacion Telefonica, INSEAD eLab , and the OECD Development Centre. "The ..... Professor Soumitra Dutta , faculty director of elab @INSEAD, and which evaluates the progress ..... Fonstad , a Senior Research Fellow at INSEAD eLab . "Much innovation in emerging markets …
-
Robust 4Q for Novartis
… the fourth quarter for the firm's Sandoz generic drug division, as the year-ago fourth quarter included a boost from the Eon Labs acquisition; excluding this impact, Sandoz sales grew 3%, and we think growth will accelerate in the coming year. Operating …
-
Solid 2Q for Novartis
… which remained flat as a percentage of sales. Overall, these results confirm our long-term positive view of Novartis, and we expect the recent acquisitions of Chiron, Hexal, and Eon Labs to bolster the company's competitive position.
-
Raising Novartis' Fair Value
… Gleevec. Furthermore, we are optimistic about the earnings contribution of the recently acquired generic companies Hexal and Eon Labs . The businesses were acquired in early 2005, and their integration into Novartis' existing generic-drug company, Sandoz …
-
Novartis Expands Generic Business
… German generic maker Hexal and U.S. generic company Eon Labs ELAB ; this will make it the largest generic drug maker in ..... ve taken a closer look at the financials of Hexal and Eon Labs . Even without this adjustment, though, we think Novartis …